---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056914"
form_type: "8-K"
ticker: null
cik: "0001851194"
company_name: "Ventyx Biosciences, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:04:31.267206+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ventyx Q1 2024 net loss $38.6M; cash $302.6M; Phase 2a trials in H2 2024

## Summary
- Net loss of $38.6M in Q1 2024 vs $38.9M in Q1 2023; R&D $33.7M, G&A $8.0M.
- Cash, cash equivalents and marketable securities of $302.6M as of March 31, 2024; runway into H2 2026.
- Phase 2a trials of CNS-penetrant NLRP3 inhibitor VTX3232 to start H2 2024 in early Parkinson's and obesity with CV risk factors.
- Phase 2 topline data for TYK2 inhibitor VTX958 in Crohn's disease expected early H2 2024; enrollment completed.
- Positive Phase 2 CAPS data for VTX2735; seeking partner for VTX002 Phase 3 in ulcerative colitis.

## SEC filing metadata
- accession: 0000950170-24-056914
- form_type: 8-K
- cik: 0001851194
- company_name: Ventyx Biosciences, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851194/000095017024056914/0000950170-24-056914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851194/000095017024056914/vtyx-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056914
- JSON: https://secwatch.observer/filing/0000950170-24-056914.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056914.txt

## Key facts
- Earnings Releases
  Ventyx Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: today announced financial results for the first quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851194/000095017024056914/0000950170-24-056914-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.